“To our knowledge, there are no reports investigating whether chlorzoxazone is a substrate of such efflux transporters; nevertheless, it cannot be ruled out that the enhanced AUC of chlorzoxazone could partly be attributed to the inhibition of efflux transport by quercetin.”
“To the Editor We read a recent publication by Bedada and Neerati on … Journal of Clinical Pharmacology with great interest, reporting the plasma concentrations of chlorzoxazone , an in vivo CYP2E1 probe drug, being significantly increased after 10-days treatment of quercetin (500 mg twice daily) in healthy subjects [1].”